Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
News & Media
Home
>
News & Media
>
Media
Media
Media
Filter by Year:
2023
2022
2021
8-Nov-2023
ASX article, 8 Nov 2023
20-Oct-2023
Neuren receives Australian Growth Company of the Year Award
26-May-2023
IRSF Physician Panel: Answering Your Questions About Trofinetide
15-May-2023
IRSF Parent Panel: My Trofinetide Clinical Trial Experience
20-Mar-2023
Proactive interview, 20 March 2023
14-Mar-2023
Ausbiz interview, 14 March 2023
13-Mar-2023
Finance News Network interview, 13 March 2023
10-Nov-2022
Neuren on Marcus Today Podcast, 7 Nov 2022
14-Sep-2022
Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference
24-Jun-2022
AusBiz interview 22 June 2022
1
2
3
Next